Compare FPI & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FPI | ZURA |
|---|---|---|
| Founded | 2013 | 2022 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 455.4M |
| IPO Year | 2013 | N/A |
| Metric | FPI | ZURA |
|---|---|---|
| Price | $10.46 | $4.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 6 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 321.1K | ★ 630.2K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.14% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $52,178,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1,049.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.37 | $0.99 |
| 52 Week High | $13.23 | $7.25 |
| Indicator | FPI | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 41.47 | 36.89 |
| Support Level | $10.14 | $3.33 |
| Resistance Level | $10.58 | $4.58 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 51.14 | 28.16 |
Farmland Partners Inc owns and seeks to acquire high-quality farmland throughout North America. The company is an internally managed real estate company which owns and contracts farmland and storage facilities located across the United States. Majority of the properties in its portfolio are used to grow primary crops, such as corn, soybeans, wheat, rice and cotton, and rest to produce specialty crops, such as almonds, pictachios, citrus, avacados, strawberies, and edible beans. The company generates its revenues through the rent it receives from its tenants.
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.